'Monotherapy' diaporamas de présentation

HIV/AIDS Medical Update

HIV/AIDS Medical Update. Arthur C. Johnson, III, M.D. HIV Clinical Director Tripler Army Medical Center. Human Immunodeficiency Virus. 2004 No new major developments in HIV care No new antiretrovirals approved. Global estimates for adults and children end 2004. People living with HIV

469 views • 29 slides

Depression and Its Treatment

Depression and Its Treatment. Les Secrest, M.D. Worldwide Depression accounts for a high level of disability and decreased functioning. Depression is a frequent occurrence with approximately 20% of the population affected by Depression. Depression is more frequent in women than in men.

596 views • 27 slides

Esophagogastric Cancer

Esophagogastric Cancer. Barbara Burtness, MD Fox Chase Cancer Center June 3, 2013. Lapatinib in combination with capecitabine plus oxaliplatin in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: The TRIO-013/LOGiC Trial.

547 views • 26 slides

Practical Considerations in Clinical Management

395 views • 24 slides

Practice Points From RA Registries and Pragmatic Trials

282 views • 19 slides

Oral Presentation #TUAB0102

Oral Presentation #TUAB0102. 48-Week Efficacy and Safety Results of Simplification to Single Agent Lopinavir/ritonavir (LPV/r) Regimen in Patients Suppressed Below 80 copies/mL on HAART - The KalMo Study.

338 views • 18 slides

odds ratio (95% confidence interval)

Meta-analysis of studies of combination vs monotherapy of life-threatening infections associated with sepsis and septic shock. .001. .01. .1. .2. .5. 1. 2. 5. 10. 100. odds ratio (95% confidence interval). Kumar et al, Crit Care Med 2010:38:1651-1664.

254 views • 7 slides

Switch to ATV/r monotherapy

Switch to ATV/r monotherapy. ATARITMO Swedish Study ACTG A5201 OREY MODAt Study. MODAt Study: switch to ATV/r monotherapy. Design. Randomisation* 1: 1 Open-label. W48. W96. ATV/ r 300/100 mg qd + 2 NRTI (continuation). ? 18 years

72 views • 7 slides

BP management Rationale for combination therapy

189 views • 5 slides

Switch to LPV/r monotherapy

Switch to LPV/r monotherapy. Pilot LPV/r M03-613 LPV/r Mono KalMo OK OK04 KALESOLO MOST HIV-NAT 077. OK Study: Switch LPV/r + 2NRTIs to LPV/r monotherapy. Design. Randomisation 1 : 1 Open-label. W48. N = 21. 42 HIV+ ? 18 years On 2 NRTIs + LPV/r > 4 weeks

53 views • 5 slides

Makani H et al. BMJ 2013;346:f360 doi : 10.1136/bmj.f360

Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for all cause mortality. Events Total. Risk ratio M-H Random (95% CI). Favours ACEi , ARB, or DRI. Favours dual RAS Blockade. 0.05. 1. 20.

171 views • 1 slides